Replies to post #129303 on Biotech Values

[DewDiligence]

SNY’s 3Q11 US sales of branded Lovenox were $184M*:

http://en.sanofi.com/Images/29017_20111103_Q3_2011_en.pdf

Since NVS reported $259M in 3Q11 sales of generic Lovenox, we now know that NVS had a 59% market share during 3Q11.

SNY’s PR at the above link confirms the launch of a Lovenox AG during October. The AG will be sold by SNY’s Winthrop business unit.

*€133M converted into dollars at the rate of $1.38, which approximates the average exchange rate during 3Q11.